News Focus
News Focus
icon url

Batermere

01/26/19 1:02 PM

#91395 RE: maplestory #91393

May I join you? I’d love to Short this POS after the RS as it nosedives back under $1. It’s inevitable with these Circus Clowns.
icon url

ignatiusrielly35

01/26/19 1:10 PM

#91396 RE: maplestory #91393

Go for it. Watch out you don’t lose 5x your investment. A RS alone means little.
icon url

zzaatt

01/26/19 3:15 PM

#91410 RE: maplestory #91393

I am ready to short this scam company after R/S for revenge.

You'd be revenging yourself!!!!

AND, it NOT a scam company, read the titles of presentations below:
(I do find the casual hissing and pissing on this company by obsessive haters rather repugnant)


The first presentation, “Neoantigen prioritization for use in a Listeria monocytogenes cancer vaccine” delivered by Brandon Coder, Ph.D., Associate Director Research & Development at Advaxis, shows the impact of CD8+ T cell responses generated to a large proportion of neoantigens, including those that were not immunogenic as peptide vaccines as well as large frameshift mutations (FSMs) that generated tumor-infiltrating lymphocytes that controlled tumor growth in preclinical CT-26 and MC-38 mouse models. The data presented support the potential of Advaxis vectors to be among the most efficient and effective at generating CD8+ T cell responses to neoantigens, including some that are not immunogenic by alternative methods of vaccination.

The second presentation, “Magnitude of anti-PSA T cell response is associated with antigen spreading and slowing in PSA and PAP velocity in ADXS-PSA treated mCRPC patients,” was delivered by Robert G. Petit, Ph.D., Chief Scientific Officer and Executive Vice President of Advaxis.

"Scam" companies don't do that sort of science, they generally sell swamp land to elderly retirees!